<?xml version="1.0" encoding="UTF-8"?>
<p id="p0015">The rapid spread of COVID-19 helps us understand the volume, diversity, and quality of resources mobilized to realize these unprecedented vaccine development speeds, especially when we compare them with the response to other global outbreaks over the last two decades (
 <xref rid="f0005" ref-type="fig">Figure 1</xref>). The first novel vaccine candidate for COVID-19 began clinical trials 1 month faster than the first candidate for the H1N1 swine flu epidemic in 2009 (93 days) and 3 months faster than the first Ebola vaccine candidate in 2014 (167 days) (
 <xref rid="ec0005" ref-type="supplementary-material">Table S1</xref> in the supplemental information online). These vaccine candidates also started clinical trials ahead of their respective outbreak peaks (
 <xref rid="f0010" ref-type="fig">Figure 2</xref>).
</p>
